Want to see PRFX full AI Analyst Report?
Top Page
PainReform
(NASDAQ:PRFX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.50
▲(87.50% Upside)
Action:Reiterated
Date:06/26/26
The score is primarily constrained by very weak financial performance—minimal revenue, large losses, and ongoing cash burn despite some improvement—creating continued funding dependence. Technicals add pressure with a clear downtrend (price below key moving averages and negative MACD). Valuation provides limited support because the negative P/E reflects unprofitable operations and no dividend yield data is available.
Positive Factors
PRF-110 preclinical vs Zynrelef
Head-to-head preclinical parity with an approved extended-release benchmark, plus slower absorption and higher local retention, supports a durable clinical differentiation. This can shape trial design, regulatory positioning and a potential product advantage for prolonged local analgesia versus competitors.
Negative Factors
Minimal revenue, large net losses
Revenue remains effectively negligible relative to expenses, so loss reduction notwithstanding, the company is far from self-sustaining. Persistently deep negative margins mean commercialization or material scale-up is required before operations can fund themselves or support sustained R&D and go-to-market activity.
Read all positive and negative factors
Positive Factors
Negative Factors
PRF-110 preclinical vs Zynrelef
Head-to-head preclinical parity with an approved extended-release benchmark, plus slower absorption and higher local retention, supports a durable clinical differentiation. This can shape trial design, regulatory positioning and a potential product advantage for prolonged local analgesia versus competitors.
Read all positive factors
PainReform (PRFX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.20M
Dividend YieldN/A
Average Volume (3M)186.11K
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-57.50
Shares Outstanding868,756
10 Day Avg. Volume213,091
30 Day Avg. Volume186,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)122.35
P/FCF Ratio-0.53
Enterprise Value/Market Cap-2.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-176.4
Revenue Forecast (FY)$10.31M
PainReform Business Overview & Revenue Model
Company Description
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a ...
PainReform Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 17.00K | 0.00 | 0.00 | 86.00K | 0.00 |
| Gross Profit | 0.00 | -827.00K | -16.00K | -15.00K | 71.00K | ― |
| EBITDA | -3.94M | -4.21M | -14.55M | -9.57M | -8.76M | -7.20M |
| Net Income | -4.09M | -4.84M | -14.59M | -9.34M | -8.79M | -7.25M |
Balance Sheet | ||||||
| Total Assets | 11.16M | 12.00M | 4.53M | 9.93M | 12.33M | 19.07M |
| Cash, Cash Equivalents and Short-Term Investments | 3.48M | 4.17M | 4.26M | 8.03M | 4.10M | 16.54M |
| Total Debt | 56.00K | 21.00K | 45.00K | 86.00K | 0.00 | 0.00 |
| Total Liabilities | 2.72M | 2.71M | 2.70M | 2.69M | 1.31M | 991.00K |
| Stockholders Equity | 8.44M | 8.54M | 1.82M | 7.24M | 11.02M | 18.08M |
Cash Flow | ||||||
| Free Cash Flow | -5.96M | -3.96M | -12.63M | -6.69M | -6.46M | -6.60M |
| Operating Cash Flow | -5.96M | -3.96M | -12.62M | -6.68M | -6.46M | -6.55M |
| Investing Cash Flow | -51.00K | -982.00K | -13.00K | 5.99M | -6.01M | -50.00K |
| Financing Cash Flow | 6.70M | 3.82M | 8.86M | 4.62M | 0.00 | 7.48M |
PainReform Technical Analysis
Negative
0.80
Price Trends
1.85
Negative
2.28
Negative
3.79
Negative
Market Momentum
-0.08
Positive
46.43
Neutral
5.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRFX, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 1.75, below the 50-day MA of 1.85, and below the 200-day MA of 3.79, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 46.43 is Neutral, neither overbought nor oversold. The STOCH value of 5.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRFX.
PainReform Risk Analysis
PainReform disclosed 46 risk factors in its most recent earnings report. PainReform reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PainReform Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $26.75M | -0.78 | -18.93% | ― | -7.07% | 75.39% | |
44 Neutral | $4.39M | -0.28 | ― | ― | ― | ― | |
43 Neutral | $11.47M | -0.29 | -63.82% | ― | 29.75% | 37.35% | |
41 Neutral | $1.20M | -0.03 | ― | ― | ― | ― | |
| ― | $2.07M | -0.05 | -9999.00% | ― | ― | 92.53% |
* Healthcare Sector Average
PRFX
PainReform
1.38
-5.62
-80.29%
CPHI
China Pharma Holdings
0.66
-1.15
-63.54%
RDHL
RedHill Biopharma
0.85
-1.18
-58.17%
COSM
Cosmos Holdings
0.18
-0.21
-53.18%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
3.25
-40.15
-92.51%
PainReform Corporate Events
PRF Technologies Unveils Stronger Preclinical Data for PRF-110 vs. ZYNRELEF
Jun 25, 2026
On June 25, 2026, Tel Aviv-based PRF Technologies reported expanded preclinical data for its lead post-operative pain candidate PRF-110 in a head-to-head study against approved extended-release analgesic ZYNRELEF. Conducted in a porcine post-opera...
PRF Technologies Secures New $15 Million Standby Equity Facility with Yorkville
Jun 18, 2026
On June 18, 2026, PRF Technologies Ltd. entered into a new standby equity purchase agreement with Yorkville fund YA II PN, LTD., giving the company the right, but not the obligation, to sell up to $15 million of its ordinary shares over 36 months....
PRF Technologies Speeds DeepSolar Predict Toward Commercial Launch for AI-Driven Renewable Revenue Optimization
May 28, 2026
On May 28, 2026, PRF Technologies announced fresh progress on DeepSolar Predict, its AI-based renewable energy revenue optimization platform, as it moves the product toward commercial launch. The system is built to shift operators beyond basic pro...
PRF Technologies’ PRF-110 Matches 72-Hour Analgesia of Approved Benchmark in Preclinical Study
May 26, 2026
On May 26, 2026, PRF Technologies reported positive preclinical data from a head-to-head study in domestic pigs showing that its lead post-operative pain candidate PRF-110 delivered sustained analgesic activity over 72 hours comparable to Zynrelef...
PRF Technologies Secures Up to $10 Million Standby Equity Facility With Yorkville
May 7, 2026
On May 7, 2026, PRF Technologies Ltd. entered into a Standby Equity Purchase Agreement with Yorkville affiliate YA II PN, LTD., giving the company the right, but not the obligation, to sell up to $10 million of its ordinary shares over 36 months. ...
PRF Technologies Wins FDA IND Clearance for OcuRing-K Phase II Cataract Trial
Apr 28, 2026
PRF Technologies Ltd., a Nasdaq-listed clinical-stage specialty pharmaceutical and technology company, develops extended-release drug-delivery solutions for post-operative pain and operates the DeepSolar platform for AI-driven energy optimization ...
PRF Technologies Posts 2025 Results as LayerBio and DeepSolar Deals Drive Dual-Platform Pivot
Mar 27, 2026
On March 27, 2026, PRF Technologies issued a year-end 2025 update detailing a strategic pivot into dual platforms in healthcare and renewable-energy analytics. The company reported a sharply reduced annual net loss of about $4.8 million versus $14...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.